lapril tablets 5 mg
شركة الشرق الاوسط للصناعات الدوائية - middle east pharmaceutical and chemical industries - enalapril maleate 5 mg - 5 mg
solu medrol 40 mg
مستودع خوري - khoury drug store - methylprednisolone 40 mg - 40 mg
solu medrol 500 mg
مستودع خوري - khoury drug store - methylprednisolone 500 mg - 500 mg
solu medrol 1000 mg
مستودع خوري - khoury drug store - methylprednisolone 1000 mg - 1000 mg
cosentyx solution for injection
novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy
besremi 250 mcg0.5 ml
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - solution for injection - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
besremi 500 mcg0.5 ml
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - solution for injection - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
entresto 25.7 mg, 24.3 mg
شركة مستودع الأدوية الأردني - the jordan drugstore co - valsartan 25.7 mg, sacubitril 24.3 mg - 25.7 mg, 24.3 mg
entresto 100mg 51.4 mg, 48.6
شركة مستودع الأدوية الأردني - the jordan drugstore co - valsartan 51.4 mg, sacubitril 48.6 - 51.4 mg, 48.6
entresto 100mg 51.4 mg, 48.6 mg
شركة مستودع الأدوية الأردني - the jordan drugstore co - valsartan 51.4 mg, sacubitril 48.6 mg - 51.4 mg, 48.6 mg